Alumis Inc. (ALMS): R&D Expense
$386.00M
Year ended 2025-12-31
$347.50M
Trailing 12 months to 2026-06-30
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $386.00M | +45.4% | 2026-03-19, From 2025-01-01 |
| 2024-12-31 | $265.55M | +92.9% | 2026-03-19, From 2024-01-01 |
| 2023-12-31 | $137.68M | n/a | 2025-03-19, From 2023-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Alumis Inc. (ALMS) | 2025-12-31 | $386.00M | +45.4% |
| Entrada Therapeutics, Inc. (TRDA) | 2025-12-31 | $142.27M | +13.5% |
| NewAmsterdam Pharma Co N.V. (NAMS) | 2025-12-31 | $141.83M | -6.3% |
| Celularity Inc (CELU) | 2025-12-31 | $15.03M | -13.6% |
| Cue Biopharma, Inc. (CUE) | 2025-12-31 | $37.74M | +4.0% |
| CASI Pharmaceuticals, Inc. (CASIF) | 2025-12-31 | $6.31M | -29.3% |
| Scynexis Inc (SCYX) | 2025-12-31 | $22.28M | -15.6% |
| Evofem Biosciences, Inc. (EVFM) | 2024-12-31 | $1.84M | -37.2% |
| Sol-Gel Technologies Ltd. (SLGL) | 2025-12-31 | $22.80M | +28.1% |
Compare ALMS, TRDA, NAMS, CELU side by side · Screen every company in Pharmaceutical Preparations ↗